Epigenetic targeting of platinum resistant testicular cancer

Daniel Sonnenburg, Michael J. Spinella, Costantine Albany

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The involvement of epigenetic aberrations in the development and progression of tumors is now well established. However, little is known of the epigenetic alterations in testicular cancer and particularly in platinum refractory germ cell tumors. Germ cell derived testicular cancers, as compared to somatic tumors, appear to have a unique epigenetic profile that features more extensive DNA hypomethylation. Emerging data from clinical specimens suggest that epigenetic aberrations, especially DNA hypermethylation, can contribute to chemotherapy resistance and poor clinical outcomes in testicular germ cell tumors. Recent data indicate that testicular cancer cells, even those resistant to platinum, are highly sensitive to low doses of demethylating agents. Based on these promising preclinical studies, we suggest that DNA methylation inhibitors in combination with chemotherapeutic agents may offer a path to overcome acquired drug resistance in testicular cancer, laying the foundation and rationale for testing this class of epigenetic drugs in the clinical setting. In this mini-review we provide a brief overview of the promise of DNA methylation therapy to treat patients with refractory cancer of the testes.

Original languageEnglish (US)
Pages (from-to)789-795
Number of pages7
JournalCurrent Cancer Drug Targets
Volume16
Issue number9
DOIs
StatePublished - Nov 1 2016

Fingerprint

Testicular Neoplasms
Platinum
Epigenomics
DNA Methylation
Germ Cell and Embryonal Neoplasms
DNA
Drug Resistance
Germ Cells
Genetic Therapy
Neoplasms
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Cisplatin resistance
  • Decitabine
  • DNA methyltransferase
  • Embryonal carcinoma
  • Epigenetics
  • Germ cell tumor
  • SGI-110
  • Testicular cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Epigenetic targeting of platinum resistant testicular cancer. / Sonnenburg, Daniel; Spinella, Michael J.; Albany, Costantine.

In: Current Cancer Drug Targets, Vol. 16, No. 9, 01.11.2016, p. 789-795.

Research output: Contribution to journalReview article

Sonnenburg, Daniel ; Spinella, Michael J. ; Albany, Costantine. / Epigenetic targeting of platinum resistant testicular cancer. In: Current Cancer Drug Targets. 2016 ; Vol. 16, No. 9. pp. 789-795.
@article{4b619177b276425d8840985baa729f7b,
title = "Epigenetic targeting of platinum resistant testicular cancer",
abstract = "The involvement of epigenetic aberrations in the development and progression of tumors is now well established. However, little is known of the epigenetic alterations in testicular cancer and particularly in platinum refractory germ cell tumors. Germ cell derived testicular cancers, as compared to somatic tumors, appear to have a unique epigenetic profile that features more extensive DNA hypomethylation. Emerging data from clinical specimens suggest that epigenetic aberrations, especially DNA hypermethylation, can contribute to chemotherapy resistance and poor clinical outcomes in testicular germ cell tumors. Recent data indicate that testicular cancer cells, even those resistant to platinum, are highly sensitive to low doses of demethylating agents. Based on these promising preclinical studies, we suggest that DNA methylation inhibitors in combination with chemotherapeutic agents may offer a path to overcome acquired drug resistance in testicular cancer, laying the foundation and rationale for testing this class of epigenetic drugs in the clinical setting. In this mini-review we provide a brief overview of the promise of DNA methylation therapy to treat patients with refractory cancer of the testes.",
keywords = "Cisplatin resistance, Decitabine, DNA methyltransferase, Embryonal carcinoma, Epigenetics, Germ cell tumor, SGI-110, Testicular cancer",
author = "Daniel Sonnenburg and Spinella, {Michael J.} and Costantine Albany",
year = "2016",
month = "11",
day = "1",
doi = "10.2174/1568009616666151222150359",
language = "English (US)",
volume = "16",
pages = "789--795",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Epigenetic targeting of platinum resistant testicular cancer

AU - Sonnenburg, Daniel

AU - Spinella, Michael J.

AU - Albany, Costantine

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The involvement of epigenetic aberrations in the development and progression of tumors is now well established. However, little is known of the epigenetic alterations in testicular cancer and particularly in platinum refractory germ cell tumors. Germ cell derived testicular cancers, as compared to somatic tumors, appear to have a unique epigenetic profile that features more extensive DNA hypomethylation. Emerging data from clinical specimens suggest that epigenetic aberrations, especially DNA hypermethylation, can contribute to chemotherapy resistance and poor clinical outcomes in testicular germ cell tumors. Recent data indicate that testicular cancer cells, even those resistant to platinum, are highly sensitive to low doses of demethylating agents. Based on these promising preclinical studies, we suggest that DNA methylation inhibitors in combination with chemotherapeutic agents may offer a path to overcome acquired drug resistance in testicular cancer, laying the foundation and rationale for testing this class of epigenetic drugs in the clinical setting. In this mini-review we provide a brief overview of the promise of DNA methylation therapy to treat patients with refractory cancer of the testes.

AB - The involvement of epigenetic aberrations in the development and progression of tumors is now well established. However, little is known of the epigenetic alterations in testicular cancer and particularly in platinum refractory germ cell tumors. Germ cell derived testicular cancers, as compared to somatic tumors, appear to have a unique epigenetic profile that features more extensive DNA hypomethylation. Emerging data from clinical specimens suggest that epigenetic aberrations, especially DNA hypermethylation, can contribute to chemotherapy resistance and poor clinical outcomes in testicular germ cell tumors. Recent data indicate that testicular cancer cells, even those resistant to platinum, are highly sensitive to low doses of demethylating agents. Based on these promising preclinical studies, we suggest that DNA methylation inhibitors in combination with chemotherapeutic agents may offer a path to overcome acquired drug resistance in testicular cancer, laying the foundation and rationale for testing this class of epigenetic drugs in the clinical setting. In this mini-review we provide a brief overview of the promise of DNA methylation therapy to treat patients with refractory cancer of the testes.

KW - Cisplatin resistance

KW - Decitabine

KW - DNA methyltransferase

KW - Embryonal carcinoma

KW - Epigenetics

KW - Germ cell tumor

KW - SGI-110

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=84995642781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995642781&partnerID=8YFLogxK

U2 - 10.2174/1568009616666151222150359

DO - 10.2174/1568009616666151222150359

M3 - Review article

C2 - 26694252

AN - SCOPUS:84995642781

VL - 16

SP - 789

EP - 795

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 9

ER -